US Patent 11332438 Creatine prodrugs, compositions and methods of use thereof

Patent 11332438 was granted and assigned to Ultragenyx Pharmaceutical on May, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Ultragenyx Pharmaceutical

Current Assignee

Ultragenyx Pharmaceutical

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11332438

Date of Patent

May 17, 2022

Patent Application Number

16764969

Date Filed

December 3, 2018

Patent Citations

‌

US Patent 10344007 Creatine prodrugs, compositions and methods of use thereof

‌

US Patent 11021501 Creatine phosphate analog prodrugs, compositions and methods of use thereof

Patent Citations Received

‌

US Patent 11753369 Creatine prodrugs, compositions and methods of use thereof

Patent Primary Examiner

‌

Joseph R Kosack

The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11332438 Creatine prodrugs, compositions and methods of use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API